Vivimed Labs Gains On Receiving Government s Approval To Make Favipiravir Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country.
Updated: May 10, 2021 12:19 pm IST
Shares of the Hyderabad-based drug maker - Vivimed Labs - were locked in a five per cent upper circuit at Rs 28.45 after it received government of India s approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg for Indian market. Vivimed Labs Limited, a niche specialty chemicals and pharmaceuticals company, announced today, the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed s own brand name Favulous across India, the company said in a press release.
Vivimed announces the receipt of Government of India approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Pathetic Situation In State, Non-Availability Of Remdesivir Injection, Medicines : Jharkhand High Court Issues Directions On COVID Management
livelaw.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livelaw.in Daily Mail and Mail on Sunday newspapers.